TRex Bio
Develops precision immunoregulatory medicines based on tissue Treg biology
$50MUndisclosed
Role not disclosedAB
Avego BioScience Capital
Activity from announced rounds
Activity in this selectionUnited States · Oct 9, 2026 · Jan 1, 2026
- Rounds participated in
- 2
- Confirmed lead rounds
- — 2 roles undisclosed
- New companies
- 2 First participation on record · 0 follow-on
- Funding in participating rounds
- $157M 2 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
2 in this selectionEpiBiologics
Develops bispecific antibodies for targeted degradation of extracellular proteins.
$107MSeries B
Role not disclosed